On the importance of population-based serological surveys of SARS-CoV-2 without overlooking their inherent uncertainties

Wu, 2020, The SARS-CoV-2 outbreak: what we know, Int. J. Infect. Dis., 94, 44, 10.1016/j.ijid.2020.03.004 Bendavid, 2020, COVID-19 antibody seroprevalence in Santa Clara County, California, 2020 Metcalf, 2016, Use of serological surveys to generate key insights into the changing global landscape of infectious disease, Lancet, 388, 728, 10.1016/S0140-6736(16)30164-7 Cairns, 2020, Covid-19 antibody tests face a very specific problem, Evaluate Vantage Kontou, 2020, Antibody tests in detecting SARS-CoV-2 infection: a meta-analysis, 2020 Rogan, 1978, Estimating prevalence from the results of a screening test, Am. J. Epidemiol., 107, 71, 10.1093/oxfordjournals.aje.a112510 Levy, 1970, A three-population model for sequential screening for bacteriuria2, Am. J. Epidemiol., 91, 148, 10.1093/oxfordjournals.aje.a121122 Gastwirth, 1987, The statistical precision of medical screening procedures: application to polygraph and AIDS antibodies test data, Stat. Sci., 2, 213, 10.1214/ss/1177013215 Reiczigel, 2010, Exact confidence limits for prevalence of a disease with an imperfect diagnostic test, Epidemiol. Infect., 138, 1674, 10.1017/S0950268810000385 Levy, 2011 Diggle, 2011, Estimating prevalence using an imperfect test, Epidemiol. Res. Int., 1–5 Lewis, 2012, A tutorial in estimating the prevalence of disease in humans and animals in the absence of a gold standard diagnostic, Emerg. Themes Epidemiol., 9, 9, 10.1186/1742-7622-9-9